Atlas Trials

Study to Evaluate Safety and Immunogenicity of the GSK Bio CMV Vaccine in CMV-seronegative Healthy Male Adult Subjects

Clinical trial NCT00435396 · COMPLETED

Trial details

NCT number
NCT00435396
Sponsor
GlaxoSmithKline
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Infections, Cytomegalovirus
Start date
2007-02-22
Primary completion
2008-08-27
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.